The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Peptide-based strategies have received an enormous amount of attention because of their
specificity and applicability. Their specificity and tumor-targeting ability are applied to …

Background A number of peptide incretin receptor agonists (IRAs) show promise as
therapeutics for Alzheimer's disease (AD) and Parkinson's disease (PD). Transport across …

Neurodegenerative diseases are common, incurable neurological disorders with high
prevalence, and lead to memory, movement, language, and intelligence impairments …

Central nervous system (CNS) diseases are among the most difficult to treat, mainly
because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach …

Animal venoms are complex mixtures containing peptides and proteins known as toxins,
which are responsible for the deleterious effect of envenomations. Across the animal …

The voltage-gated potassium channel KV 1.3 is a well-established therapeutic target for a
range of autoimmune diseases, in addition to being the site of action of many venom-derived …

RNA, including mRNA, siRNA and miRNA, is part of a new class of patient treatments that
prevent and treat several diseases. As an alternative to DNA therapy using plasmid DNA …

Biologic drugs are large molecule pharmaceuticals that do not cross the blood–brain barrier
(BBB), which is formed by the brain capillary endothelium. Biologics can be re-engineered …

Abstract P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) are two
transporters expressed in human neural stem/progenitor cells and at the Blood-Brain Barrier …